Of 20 carefully studied patients with angina pectoris given oral visammin, 4 had a significant reduction in number of pains. Eleven stated that their pains were less severe and less easily precipitated while taking visammin. There was questionable improvement in the exercise tolerance test in 2 of 9 patients after oral visammin therapy. The daily oral dose ranged from 40 mg. to 240 mg. Undesirable side effects were encountered in 17 of the 20 patients. Parenteral administration of visammin was evaluated by means of the ballistocardiograph, the exercise tolerance test, and by tilting.
INTRODUCTION
K jr HELLIN, now officially called visam- min,' has been reported to be a potent coronary vasodilator in animal experiments.2' 3 Anrep, Kenawy, and Barsoum4 have summarized the history, pharmacology, and early clinical trials with the drug. In addition they found distinct clinical improvement in 140 of 250 patients with angina pectoris that were treated with visammin. Ayad5 reported good results with visammin in 19 of 23 patients treated. Rosenman and co-workers in a series of 14 patients with angina reported a good response to visammin in eleven. 6 Osher and Katz7 reported subjective or objective improvement in 16 of 19 patients. Greiner and Gold,8 however, in a comparative study on patients with angina have found visammin to be no better than placebo.
In order to evaluate further the therapeutic value of visammin in angina pectoris, the present study, employing both subjective and objective means on a group of controlled patients, was undertaken. Aided by a grant from the Smith, Kline, and French Laboratories, Philadelphia, Pennsylvania, who supplied us with all Eskel (visammin) used in this study. 80 
METHODS AND MATERIALS
Twenty-three patients who presented a reliable and typical clinical story of angina pectoris were selected from the Cardiac and Medical Clinics of the Cincinnati General Hospital for studies with oral and parenteral administration of visammin. Each patient was given a small card made in the form of a calendar on which he was instructed to enter the number of pains during each day. All patients were allowed to take nitroglycerin tablets as often as they needed. Some patients required maintenance digitalis and this medication was not changed. These patients were observed by one of us for a control period up to six weeks prior to the administration of either visammin or placebo.
The effect of oral administration of visammin (40 mg. per tablet) and of a placebo of identical appearance was compared in 20 patients. The 
Ballistocardiography
Four of the 8 patients who received visammin had abnormal control ballistocardiographic records. Cardiac output was not computed in these four.'8 However, no change in contour or amplitude of the ballistocardiographic complexes occurred after the injection of visammin.
The remaining 4 patients had normal records permitting calculation of cardiac output. One showed an increase over 10 per cent of the basal value, while 3 demonstrated a decrease after parenteral visammin. These changes in cardiac output were transient. The interval between time of injection and the occurrence of maximal change in cardiac output varied.
In the 2 eontrol subjects, in whom saline placebos were substituted for visammin, no significant change in cardiac output was observed.
No significant change in the blood pressure or pulse rate was noted following intramuscular administration of visammin. All patients receiving visammin intramuscularly complained of burning pain at the site of injection.
Tilting
The reflex blood pressure responses to tilting were studied in 6 patients (cases 5, 6 We have attempted to overcome some of these difficulties. Each patient was observed for a control period prior to the administration of any preparation. The duration of study was for periods up to 11 months in some patients, thus helping to minimize the influence of seasonal temperature variation. The same physician folloswed the patients and administered all medication. This physician did not know whether he was administering visammin or placebo until the study was completed. Many of the patients had been instructed in the past to take nitroglycerin tablets in anticipation of pains. Therefore, the number of actual attacks of angina pectoris was used as a criterion of frequency of seizures rather than the number of nitroglycerin tablets used. In addition an attempt was made to compare the severity of attacks in a given patient before and after visammin therapy. Improvement due to visammin therapy has been determined in a number of ways by various investigators. Anrep, Kenawy, and Barsoum4 described a marked reduction in frequency of attacks in 140, a moderate reduction in 85, and no change in 25 of 250 patients studied. Rosenman, Fishman, Kaplan, Levin, and Katz,6 using both a decrease in the number of attacks and a decrease in the number of glyceryl trinitrate tablets taken as an index of improvement, found good results in 11 of 14 patients. Osher and Katz,7 using the number of nitroglycerin tablets taken per week as a guide to the frequency of attacks, found improvement in 16 of 19 patients. Our results differ markedly from those obtained by the above investigators in that a decrease in the number of attacks was observed in only 4 of 20 patients while on visammin therapy.
Rosenman and co-workers6 also state that there was increased capacity for exercise and increased sense of well-being while on oral visammin in 1 ble explanations for these discrepancies. The course of angina, as has already been mentioned, is variable and extremely difficult to study. The methods of evaluation of response employed by the various workers have all been slightly different. However, the most apparent reason for the discrepancies in the reports lies in the dosage employed.
Osher and Katz employed 120 mg. or more per day in all cases who showed improvement. Rosenman and associates used as high as 300 mg. (240 mg. by improved assay) per day in 9 of their 14 patients. We were not able to administer such high doses in as large number of patients because of the high incidence of side reactions in our series. None of the side effects we encountered were considered severe except in one patient (case 12, R. H.). Nevertheless, they were sufficiently troublesome that many patients were unable to take the prescribed number of tablets every day. It may be that because of this, a sufficiently high therapeutic drug level was not adequately maintained in all cases. As can be seen in 4 . Cardiac output as measured by the ballistocardiograph following intramuscular visammin increased in only one of 8 patients.
5. Pressor and depressor blood pressure reflexes induced by tilting showed no change after parenteral visammin in 6 cases studied. 6 . Undesirable side effects were frequently encountered and were more common with daily dosages of 120 mg. or more. 7. We believe that visammin does have therapeutic value in the treatment of angina but that at present the high frequency of undesirable side effects prevents many patients from taking an adequate dose to achieve benefit.
